- Home
- ADVB vs DRCT Comparison
ADVB vs DRCT Comparison
Compare ADVB & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADVB | DRCT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 8.9M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ADVB | DRCT |
|---|---|---|
| Price | $0.39 | $0.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 1.3M | ★ 24.1M |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,369,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $0.07 |
| 52 Week High | $4.10 | $6.59 |
Technical Indicators
Market Signals| Indicator | ADVB | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 22.58 |
| Support Level | $0.32 | $0.09 |
| Resistance Level | $0.42 | $0.09 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 45.11 | 3.26 |
Price Performance
Historical ComparisonAbout ADVB Advanced Biomed Inc.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.